Overview

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.

Phase:

Phase 3

Details

Lead Sponsor:

Optinose US Inc.

Treatments:

Sumatriptan